{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:06:40Z","timestamp":1787162800270,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00520-026-10562-9","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:35:24Z","timestamp":1774683324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-2975","authenticated-orcid":false,"given":"Natalya","family":"Alekhina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-5646","authenticated-orcid":false,"given":"Kathi","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-4031","authenticated-orcid":false,"given":"Katherine","family":"Sward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1386-4505","authenticated-orcid":false,"given":"Bob","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-4778","authenticated-orcid":false,"given":"Wallace","family":"Akerley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"9","key":"10562_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10562_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som A, Mandaliya R, Alsaadi D et al (2019) Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases 7(4):405\u2013418. https:\/\/doi.org\/10.12998\/wjcc.v7.i4.405","journal-title":"World J Clin Cases"},{"issue":"2","key":"10562_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jgo.2021.10.002","volume":"13","author":"D Ksienski","year":"2022","unstructured":"Ksienski D, Truong PT, Croteau NS et al (2022) Immune-related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab. J Geriatr Oncol 13(2):220\u2013227. https:\/\/doi.org\/10.1016\/j.jgo.2021.10.002","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"10562_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/CJI.0000000000000383","volume":"44","author":"AN Tran","year":"2021","unstructured":"Tran AN, Wang M, Hundt M et al (2021) Immune checkpoint inhibitor-associated diarrhea and colitis: A systematic review and meta-analysis of observational studies. J Immunother 44(8):325\u2013334. https:\/\/doi.org\/10.1097\/CJI.0000000000000383","journal-title":"J Immunother"},{"key":"10562_CR5","unstructured":"National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities (Version 1.2026). NCCN Clinical Practice Guidelines in Oncology. Published 2026. Accessed February 26, 2026. https:\/\/www.nccn.org"},{"issue":"5","key":"10562_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00384-019-03268-4","volume":"34","author":"F Ca\u00f1ete","year":"2019","unstructured":"Ca\u00f1ete F, Ma\u00f1osa M, Lobat\u00f3n T et al (2019) Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike: Report of new cases and review of the literature. Int J Colorectal Dis 34(5):861\u2013865. https:\/\/doi.org\/10.1007\/s00384-019-03268-4","journal-title":"Int J Colorectal Dis"},{"key":"10562_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284819884196","volume":"12","author":"UN Shivaji","year":"2019","unstructured":"Shivaji UN, Jeffery L, Gui X et al (2019) Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Ther Adv Gastroenterol 12:1\u201315. https:\/\/doi.org\/10.1177\/1756284819884196","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"10562_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1634\/theoncologist.2018-0304","volume":"25","author":"BP Singh","year":"2020","unstructured":"Singh BP, Marshall JL, He AR (2020) Workup and management of immune-mediated colitis in patients treated with immune checkpoint inhibitors. Oncologist 25(3):197\u2013202. https:\/\/doi.org\/10.1634\/theoncologist.2018-0304","journal-title":"Oncologist"},{"issue":"8","key":"10562_CR9","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1007\/s00520-022-06948-0","volume":"30","author":"HR Wardill","year":"2022","unstructured":"Wardill HR, Chan RJ, Chan A et al (2022) Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: Supportive care implications and recommendations. Support Care Cancer 30(8):6369\u20136373. https:\/\/doi.org\/10.1007\/s00520-022-06948-0","journal-title":"Support Care Cancer"},{"key":"10562_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109275","volume":"132","author":"H Park","year":"2020","unstructured":"Park H, Hatabu H, Ricciuti B et al (2020) Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol 132:109275. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109275","journal-title":"Eur J Radiol"},{"issue":"5","key":"10562_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4291\/wjgp.v10.i5.54","volume":"10","author":"MG Rubio","year":"2019","unstructured":"Rubio MG, Amo-Mensah K, Gray JM et al (2019) Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol 10(5):54\u201363. https:\/\/doi.org\/10.4291\/wjgp.v10.i5.54","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10562_CR12","doi-asserted-by":"publisher","unstructured":"Losurdo G, Angelillo D, Favia N et al (2023) Checkpoint inhibitor-induced colitis: an update. Biomed11(5):1496. https:\/\/doi.org\/10.3390\/biomedicines11051496","DOI":"10.3390\/biomedicines11051496"},{"issue":"14\u201315","key":"10562_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/1750743X.2024.2386234","volume":"16","author":"R Lukin","year":"2024","unstructured":"Lukin R, Ciner A (2024) Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report. Immunotherapy 16(14\u201315):943\u2013948. https:\/\/doi.org\/10.1080\/1750743X.2024.2386234","journal-title":"Immunotherapy"},{"key":"10562_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1292122","volume":"15","author":"T Yan","year":"2024","unstructured":"Yan T, Yu L, Zhang J et al (2024) Achilles\u2019 heel of currently approved immune checkpoint inhibitors: immune-related adverse events. Front Immunol 15:1292122. https:\/\/doi.org\/10.3389\/fimmu.2024.1292122","journal-title":"Front Immunol"},{"key":"10562_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"issue":"30","key":"10562_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3238\/arztebl.2011.0515","volume":"108","author":"R Kwiecien","year":"2011","unstructured":"Kwiecien R, Kopp-Schneider A, Blettner M (2011) Concordance analysis. Dtsch Arztebl Int 108(30):515\u2013521. https:\/\/doi.org\/10.3238\/arztebl.2011.0515","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10562_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0714-x","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Herrera LN, Tang T et al (2019) Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 7(1):242. https:\/\/doi.org\/10.1186\/s40425-019-0714-x","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10562_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/OP.20.00002","volume":"16","author":"Z Gong","year":"2020","unstructured":"Gong Z, Wang Y (2020) Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 16(8):453\u2013461. https:\/\/doi.org\/10.1200\/OP.20.00002","journal-title":"JCO Oncol Pract"},{"key":"10562_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N et al (2022) Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol 13:779691. https:\/\/doi.org\/10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"issue":"11","key":"10562_CR20","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.1007\/s00432-023-04792-1","volume":"149","author":"J Gao","year":"2023","unstructured":"Gao J, Zhang P, Tang M et al (2023) Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis. J Cancer Res Clin Oncol 149(11):8993\u20139006. https:\/\/doi.org\/10.1007\/s00432-023-04792-1","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10562_CR21","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.3747\/co.25.4047","volume":"25","author":"A Kartolo","year":"2018","unstructured":"Kartolo A, Sattar J, Sahai V et al (2018) Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol 25(5):e403\u2013e410. https:\/\/doi.org\/10.3747\/co.25.4047","journal-title":"Curr Oncol"},{"issue":"1","key":"10562_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/21645515.2020.1769398","volume":"17","author":"N Hussain","year":"2021","unstructured":"Hussain N, Naeem M, Pinato DJ (2021) Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? Hum Vaccin Immunother 17(1):55\u201361. https:\/\/doi.org\/10.1080\/21645515.2020.1769398","journal-title":"Hum Vaccin Immunother"},{"key":"10562_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","volume":"157","author":"M Kostine","year":"2021","unstructured":"Kostine M, Mauric E, Tison A et al (2021) Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 157:474\u2013484. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.036","journal-title":"Eur J Cancer"},{"issue":"3","key":"10562_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000507579","volume":"5","author":"J Burla","year":"2020","unstructured":"Burla J, Bluemel S, Biedermann L et al (2020) Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm Intest Dis 5(3):109\u2013116. https:\/\/doi.org\/10.1159\/000507579","journal-title":"Inflamm Intest Dis"},{"issue":"4","key":"10562_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000585","volume":"5","author":"DM Favara","year":"2020","unstructured":"Favara DM, Spain L, Au L et al (2020) Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open 5(4):e000585. https:\/\/doi.org\/10.1136\/esmoopen-2019-000585","journal-title":"ESMO Open"},{"issue":"3","key":"10562_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaad.2019.07.049","volume":"82","author":"GE Molina","year":"2020","unstructured":"Molina GE, Allen IM, Hughes MS et al (2020) Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: a retrospective cohort study. J Am Acad Dermatol 82(3):743\u2013746. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.049","journal-title":"J Am Acad Dermatol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10562-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:41:07Z","timestamp":1776235267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10562-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10562"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10562-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8264047\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board approved the study protocol (IRB #00176995) and granted a waiver of informed consent under 45 CFR 46.116(f) and 45 CFR 164.512(i)(2)(ii).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"380"}}